Genetic and epigenetic regulation on the transcription of GABRB2 : Genotype-dependent hydroxymethylation and methylation alterations in schizophrenia

Zong, Lu; Zhou, Lin; Hou, Yu; Zhang, Lulu; Jiang, Wei; Zhang, Wenwei; Wang, Limin; Luo, Xia; Wang, Shi‐Qing; Deng, Cong; Peng, Zhizhen; Li, Shufen; Hu, Jiming; Zhao, Hu; Zhao, Chen

doi:10.1016/j.jpsychires.2016.12.019

Cited by 29 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our systematic review yielded 29 studies (Table 1). Eighteen studies analyzed methylation in patients with schizophrenia, four studies in patients with bipolar disorder, and seven studies in a combined sample of patients with schizophrenia and bipolar disorder. The majority (n=22) of studies included observational sampling, such as cross‐sectional or case‐control studies, and the remaining analyzed changes in a prospective manner.…”

Section: Resultsmentioning

confidence: 99%

“…Finally, the method of DNA methylation assessment ranged from global to genome‐wide and targeted gene analysis. All studies analyzed 5‐methylcytosine methylation with the exception of one study who simultaneously analyzed 5‐hydroxymethylcytosine gene methylation (an “oxidized derivative” form of 5‐methylcytosine) . Unless otherwise stated, all summarized results refer to 5‐methylcytosine DNA methylation.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Antipsychotic Medications and DNA Methylation in Schizophrenia and Bipolar Disorder: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

The pharmacoepigenetics of antipsychotic treatment in severe mental illness is a growing area of research that aims to understand the interface between antipsychotic treatment and genetic regulation. Pharmacoepigenetics may some day assist in identifying treatment response mechanisms or become one of the components in the implementation of precision medicine. To understand the current evidence regarding the effects of antipsychotics on DNA methylation a systematic review with qualitative synthesis was performed through Pubmed, Embase and Psychinfo from earliest data to June 2019. Studies were included if they analyzed DNA methylation in an antipsychotic‐treated population of patients with schizophrenia or bipolar disorder. Data extraction occurred via a standardized format and study quality was assessed. Twenty‐nine studies were identified for inclusion. Study design, antipsychotic type, sample source, and methods of DNA methylation measurement varied across all studies. Eighteen studies analyzed methylation in patients with schizophrenia, four studies in patients with bipolar disorder, and seven studies in a combined sample of schizophrenia and bipolar disorder. Twenty‐two studies used observational samples whereas the remainder used prospectively treated samples. Six studies assessed global methylation, five assessed epigenome‐wide, and 15 performed a candidate epigenetic study. Two studies analyzed both global and gene‐specific methylation, whereas one study performed a simultaneous epigenome‐wide and gene‐specific study. Only three genes were analyzed in more than one gene‐specific study and the findings were discordant. The state of the pharmacoepigenetic literature on antipsychotic use is still in its early stages and uniform reporting of methylation site information is needed. Future work should concentrate on using prospective sampling with appropriate control groups and begin to replicate many of the novel associations that have been reported.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Antipsychotic Medications and DNA Methylation in Schizophrenia and Bipolar Disorder: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The interactions between genotype, DNA methylation, and gene expression in schizophrenia have been documented in previous studies. Some of these studies were related to the COMT gene, while others were not . There were nine documented single nucleotide polymorphisms (SNP) within the 109bp of the CpG island’s rich studied region.…”

Section: Discussionmentioning

confidence: 99%

“…Some of these studies 15,51 were related to the COMT gene, while others were not. 52,53 There were nine documented single nucleotide polymorphisms (SNP) within the 109bp of the CpG island's rich studied region. The minor allele frequency (MAF) of these nine SNP was extremely rare with estimated frequency of <0.1% (Chr22: 19 941 607-19 969 975; www.ensembl.org).…”

Section: Comt Mrna Expression Analysismentioning

confidence: 99%

DNA methylation of membrane‐bound catechol‐O‐methyltransferase in Malaysian schizophrenia patients

Huda

Norsidah

Fikri

et al. 2017

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

show abstract

“…56 Additionally, the risk variants co-localized with genetically controlled DNA methylation regions. 56 The discovery of multiple DNA methylation loci under genetic influence is in line with candidate-gene approaches showing genetically dependent epigenetic status at other risk genes, including the GABA receptor subunit (GABRB2), 57 catechol-O-methyltransferase (COMT [58][59][60] and cannabinoid receptor (CNR1 61 risk genes, involved in neurotransmission alone or in combination with established environmental risk factors, such as cannabis smoking.…”

Section: Cross Talk Between the Genome And The Epigenome In The Vulnementioning

confidence: 94%

Epigenetics applied to psychiatry: Clinical opportunities and future challenges

Kular

2018

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Psychiatric disorders are clinically heterogeneous and debilitating chronic diseases resulting from a complex interplay between gene variants and environmental factors. Epigenetic processes, such as DNA methylation and histone posttranslational modifications, instruct the cell/tissue to correctly interpret external signals and adjust its functions accordingly. Given that epigenetic modifications are sensitive to environment, stable, and reversible, epigenetic studies in psychiatry could represent a promising approach to better understanding and treating disease. In the present review, we aim to discuss the clinical opportunities and challenges arising from the epigenetic research in psychiatry. Using selected examples, we first recapitulate key findings supporting the role of adverse life events, alone or in combination with genetic risk, in epigenetic programming of neuropsychiatric systems. Epigenetic studies further report encouraging findings about the use of methylation changes as diagnostic markers of disease phenotype and predictive tools of progression and response to treatment. Then we discuss the potential of using targeted epigenetic pharmacotherapy, combined with psychosocial interventions, for future personalized medicine for patients. Finally, we review the methodological limitations that could hinder interpretation of epigenetic data in psychiatry. They mainly arise from heterogeneity at the individual and tissue level and require future strategies in order to reinforce the biological relevance of epigenetic data and its translational use in psychiatry. Overall, we suggest that epigenetics could provide new insights into a more comprehensive interpretation of mental illness and might eventually improve the nosology, treatment, and prevention of psychiatric disorders.

show abstract

Genetic and epigenetic regulation on the transcription of GABRB2 : Genotype-dependent hydroxymethylation and methylation alterations in schizophrenia

Cited by 29 publications

References 26 publications

Antipsychotic Medications and DNA Methylation in Schizophrenia and Bipolar Disorder: A Systematic Review

Antipsychotic Medications and DNA Methylation in Schizophrenia and Bipolar Disorder: A Systematic Review

DNA methylation of membrane‐bound catechol‐O‐methyltransferase in Malaysian schizophrenia patients

Epigenetics applied to psychiatry: Clinical opportunities and future challenges

Contact Info

Product

Resources

About